Minjuvi
What Minjuvi is used for
Minjuvi is indicated in combination with lenalidomide followed by Minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- Conditional approval: approved on less complete data because the need is high; more data must follow.
Key facts
- Brand
- Minjuvi
- Active substance
- tafasitamab
- Disease area
- Lymphoma, Large B-Cell, Diffuse
- Medicine group
- Antineoplastic agents
- ATC code
- L01FX12
- Marketing authorisation holder
- Incyte Biosciences Distribution B.V.
- Authorised in the EU since
- 2021
Official information
In the USA
Same active substance: Monjuvi
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Minjuvi used for?
Minjuvi is indicated in combination with lenalidomide followed by Minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).
What is the active substance in Minjuvi?
Minjuvi contains tafasitamab.
Who makes Minjuvi?
The EU marketing authorisation holder is Incyte Biosciences Distribution B.V..
Is Minjuvi an orphan medicine?
Yes. Minjuvi is designated an orphan medicine in the EU, for a rare disease (Lymphoma, Large B-Cell, Diffuse).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU